📜 History of Psychedelic Mushrooms

Overview: A History Spanning Millennia

The relationship between human beings and psilocybin-containing mushrooms is, by most evidence, ancient — predating written language, the major world religions, and recorded history as conventionally understood. What we know of that ancient relationship comes from rock art, pre-Columbian artefacts, surviving oral traditions, and the continuing practices of indigenous communities in Mesoamerica and elsewhere. What we know of its modern chapter comes from the work of a small number of scientists, writers, and cultural figures who, from the 1950s onward, brought psilocybin mushrooms into the Western scientific and cultural consciousness — with consequences that continue to unfold today.

The history of psilocybin mushrooms is not a smooth arc. It includes long periods of suppression — by colonial authorities who outlawed indigenous ceremonial practices, and by modern governments who criminalised psychedelic substances during the 1970s — as well as periods of extraordinary scientific and cultural productivity. Understanding this history matters for harm reduction: it provides context for why these substances are still illegal in most jurisdictions, explains the gaps in the research record, and illuminates why indigenous knowledge and community practice have preserved what institutional science could not.

Timeline Overview

• c. 9000–7000 BCE: Rock art at Tassili n'Ajjer (Algeria) — possible earliest depictions of mushroom use
• c. 1500 BCE–1500 CE: Pre-Columbian Mesoamerican ceremonial use; Aztec teonanácatl tradition
• c. 1500–1900: Colonial suppression of indigenous ceremonial practices across Mesoamerica
• 1936: Anthropologist Blas Pablo Reko first documents surviving Mazatec mushroom ceremonies
• 1955: R. Gordon Wasson participates in Mazatec ceremony with Maria Sabina
• 1957: Wasson's account published in Life magazine — Western introduction to "magic mushrooms"
• 1958: Albert Hofmann isolates and synthesises psilocybin at Sandoz Laboratories
• 1960–1963: Harvard Psilocybin Project under Timothy Leary and Richard Alpert
• 1968–1970: Psilocybin criminalised in the US; Schedule I under the Controlled Substances Act 1970
• 1970s–1990s: Underground research continues; Alexander Shulgin's contributions; ethnobotanical documentation
• 1991–1995: Rick Strassman's DMT research at University of New Mexico — first approved psychedelic research in decades
• 2006: Johns Hopkins psilocybin study (Griffiths et al.) — landmark clinical research relaunches field
• 2012–present: Imperial College London neuroimaging studies; MAPS MDMA trials; proliferation of clinical research
• 2020: Oregon Ballot Measure 109 passes — first US state-level therapeutic psilocybin legalisation
• 2022: Colorado Proposition 122 passes — decriminalisation and regulated access

Part I: Ancient and Indigenous Use

The Tassili n'Ajjer Rock Art (c. 9000–7000 BCE)

The Tassili n'Ajjer plateau in southern Algeria, now a UNESCO World Heritage site, contains one of the world's largest collections of prehistoric rock art — tens of thousands of paintings and engravings created over roughly 10,000 years. Among them, some scholars have identified what appear to be human figures with mushroom-like forms emerging from their bodies or held in their hands.

The most frequently cited image, sometimes called the "Mushroom Shaman," shows a figure whose body appears adorned with mushroom-shaped objects. Ethnobotanist Giorgio Samorini and others have interpreted these images as evidence of ceremonial mushroom use in North Africa during the Neolithic period. However, this interpretation is contested. Archaeologists note that the relationship between rock art imagery and actual practices is difficult to establish, and that the mushroom identification is not certain. The images cannot confirm specific species, dosage, or cultural meaning with current evidence.

Nevertheless, the Tassili images represent one of the most provocative and frequently cited pieces of evidence for the ancient human relationship with psychoactive substances. Whether or not they depict psilocybin mushrooms specifically, they reflect a long tradition of depicting altered states of consciousness in human cultural expression.

Mesoamerican Ceremonial Traditions

The most unambiguous evidence for pre-Columbian psilocybin mushroom use comes from Mesoamerica, where multiple converging lines of evidence — archaeological, iconographic, and ethnohistorical — confirm the ceremonial use of psilocybin-containing mushrooms among several cultures, including the Aztec, Mazatec, Mixtec, Zapotec, and others.

The Aztec name for sacred mushrooms, teonanácatl (often translated as "flesh of the gods" or "divine mushroom"), appears in sixteenth-century Spanish colonial records. Franciscan friar Bernardino de Sahagún documented mushroom use in his Florentine Codex (compiled c. 1545–1590), describing how mushrooms were consumed at ceremonial feasts, sometimes with honey, producing visions, emotional states, and communications with the divine. Sahagún's account is detailed and clearly describes a psychoactive substance of great cultural significance.

Pre-Columbian stone artefacts known as "mushroom stones" — carved stone figures with distinctly mushroom-shaped heads — have been found throughout Mesoamerica, particularly in Guatemala and southern Mexico. Dating to approximately 1000 BCE to 900 CE, these artefacts are now widely interpreted as ritual objects associated with mushroom ceremonies. They represent some of the most tangible archaeological evidence of the deep cultural importance of psilocybin mushrooms in pre-Columbian society.

The Mixtec Codex Vindobonensis (c. 1350 CE), one of the few surviving pre-Columbian screenfold books, contains images that many scholars interpret as depictions of deity figures holding mushrooms — further evidence of mushroom ritual at the highest levels of Aztec and Mixtec religious practice.

Colonial Suppression

When Spanish colonisers arrived in Mesoamerica in the early sixteenth century, they encountered indigenous mushroom ceremonies and quickly moved to suppress them. The Spanish Inquisition and associated civil authorities categorised mushroom ceremonies as devil worship, idolatry, and heresy. Indigenous practitioners were punished, ceremonies were driven underground, and colonial authorities worked systematically to erase documentation of pre-Columbian religious practices.

Despite roughly four centuries of suppression, mushroom ceremonies did not disappear. They were maintained in remote communities, particularly in the mountainous regions of Oaxaca, where the Mazatec people continued their velada (night ceremony) tradition in relative isolation. This cultural continuity — preserving knowledge and practice through centuries of persecution — is one of the most remarkable facts about the history of psilocybin mushrooms, and it is the foundation on which the modern era was built.

The Mazatec Tradition and Maria Sabina

Among all indigenous groups who maintained mushroom ceremony traditions, the Mazatec people of Oaxaca, Mexico became central to the twentieth-century rediscovery of psilocybin. The Mazatec term for psilocybin mushrooms is nti si tho, sometimes translated as "the little ones who spring up" — a reference to the mushrooms' rapid fruiting after rain.

Mazatec veladas are night-long ceremonies conducted by a curandera or curandero (healer), in which sacred mushrooms are consumed for healing, divination, and spiritual communication. The ceremony involves specific prayers, chants, and ritual songs — cantos — that are central to the healing process. The mushrooms are understood not as a recreational substance but as a medium for communication with healing spirits and divine forces.

Maria Sabina (1894–1985) was the Mazatec curandera whose ceremonies became known to the outside world through R. Gordon Wasson's 1957 account. Sabina is now a revered figure in both indigenous Mazatec culture and the broader psychedelic counterculture, but her relationship with the outside world's attention was complicated and often painful. The influx of Westerners seeking her ceremonies disrupted her community, and she was ostracised by some community members who felt she had violated the sacred privacy of the ceremonies by allowing outsiders. Her legacy reflects the ethical complexities of cultural exchange and the particular vulnerability of indigenous traditions to appropriation and commodification.

Part II: The Western Discovery (1950s)

R. Gordon Wasson and the Life Magazine Article (1957)

Robert Gordon Wasson (1898–1986) was a banker by profession and an amateur mycologist by passion. His interest in mushrooms began, by his own account, from a disagreement with his wife about the cultural attitude toward mushrooms: she was from a mushroom-loving culture (Russian); he from a mycophobic one (Anglo-American). This difference sparked decades of research into the cultural attitudes toward mushrooms across civilisations.

In 1953, Wasson received information about surviving mushroom ceremonies in Mexico from ethnobotanist Richard Evans Schultes, who had visited the region in 1937–38. Wasson subsequently made several trips to the Sierra Mazateca region of Oaxaca. In 1955, he participated in a velada conducted by Maria Sabina — an event he described as one of the most significant experiences of his life.

On 13 May 1957, Life magazine published Wasson's account under the headline "Seeking the Magic Mushroom." The article was an extraordinary document for its time: a mainstream American magazine publishing a serious, reverential account of a psychedelic ceremony by a member of the financial and cultural establishment. Wasson's writing was careful, respectful of the Mazatec tradition, and precise about the phenomenology of the experience. He coined the term "magic mushroom" in this article — a phrase that, for better or worse, has defined public discourse about psilocybin ever since.

The impact of the Life article was immediate and lasting. It triggered Western curiosity about psilocybin mushrooms on a scale that no previous publication had achieved. It also, as Wasson himself later lamented, opened the floodgates of Western tourism to Maria Sabina's community, contributing to the disruption he had not intended.

Albert Hofmann Isolates Psilocybin (1958)

Albert Hofmann (1906–2008) is one of the most significant figures in the history of psychopharmacology. Working as a chemist at Sandoz Laboratories in Basel, Switzerland, he had already synthesised LSD (lysergic acid diethylamide) in 1938 and accidentally discovered its potent psychological effects in 1943. When Wasson's work on Mexican mushrooms came to his attention, Hofmann obtained samples of Psilocybe mexicana from the mushroom's natural habitat and began systematic chemical analysis.

In 1958, Hofmann successfully isolated the primary active compounds from P. mexicana, naming them psilocybin and psilocin. He then synthesised both compounds chemically — an achievement that meant their effects could be studied in controlled conditions without requiring the mushroom itself. To confirm his synthesis was correct and active, Hofmann self-administered 32 mg of synthetic psilocybin and experienced the effects directly.

Hofmann's 1958 achievement established psilocybin as a defined, reproducible chemical compound — a critical step for scientific research. His subsequent work with Maria Sabina, to whom he sent tablets of synthetic psilocybin in 1962 (she reportedly confirmed they produced the same effects as the mushrooms), created a bridge between indigenous knowledge and Western pharmacology that remains remarkable in the history of ethnobotany. Hofmann lived to 102 and remained a thoughtful advocate for the therapeutic potential of psilocybin until his death in 2008.

Part III: The 1960s — Rapid Rise and Abrupt Halt

The Harvard Psilocybin Project (1960–1963)

In 1960, Timothy Leary (1920–1996) — then a lecturer in clinical psychology at Harvard University — first tried psilocybin mushrooms while on a trip to Mexico. The experience, he later said, was more educational than his entire academic career. On returning to Harvard, Leary established the Harvard Psilocybin Project with his colleague Richard Alpert (later Baba Ram Dass, 1931–2019).

Between 1960 and 1963, the project conducted a series of studies using psilocybin with graduate students, convicts, theologians, and artists. The most famous of these was the Concord Prison Experiment, in which psilocybin sessions with inmates were combined with group therapy and followed up after release to assess recidivism. Leary reported dramatically reduced recidivism rates — though subsequent scrutiny of the data raised methodological questions. The Marsh Chapel Experiment (Good Friday Experiment, 1962), conducted by Walter Pahnke under Leary's supervision, gave psilocybin or placebo to divinity students during a religious service and assessed mystical experience — a study that became foundational to later research on the religious and therapeutic potential of psilocybin.

The Harvard project was controversial from the beginning. Concerns were raised about appropriate supervision, the involvement of undergraduates, and the increasingly evangelical tone Leary was adopting in his public statements. In 1963, Leary and Alpert were dismissed from Harvard — the first dismissals of Harvard faculty in the university's modern history. The project ended, but its influence on the emerging counterculture was already substantial.

The Counterculture and the First Wave of Public Interest

Through the mid-1960s, psilocybin (alongside LSD, which had reached the wider public through Ken Kesey's Merry Pranksters and other vectors) became embedded in the cultural fabric of the American and British counterculture. Writers, musicians, artists, and activists reported using psychedelics. The Beatles' experimentation with psychedelics, widely publicised, accelerated mainstream curiosity. Academic figures including Aldous Huxley (who wrote The Doors of Perception about mescaline in 1954 and corresponded with Leary about psilocybin) gave the emerging psychedelic conversation a degree of intellectual credibility.

This cultural moment also produced a significant backlash. Media coverage of psychedelic experiences increasingly emphasised adverse events — psychiatric hospitalisations, accidents, and moral panic about young people abandoning conventional life. By the late 1960s, the political climate had turned decisively against psychedelic substances.

Criminalisation: The Controlled Substances Act (1970)

The US Controlled Substances Act (CSA) was signed into law by President Richard Nixon on October 27, 1970. Psilocybin was placed in Schedule I — the most restrictive category, reserved for substances deemed to have no accepted medical use, a high potential for abuse, and a lack of accepted safety for use under medical supervision. Schedule I status effectively halted clinical research on psilocybin in the United States: it required researchers to obtain DEA Schedule I research licenses, use only federally approved sources of the substance, conduct research in approved facilities, and navigate a regulatory process that most institutional review boards were unwilling to engage with.

Nixon's declaration of a "War on Drugs" in 1971 — a phrase used in a press conference on June 17, 1971 — established drug policy as a domestic security and law enforcement issue rather than a public health matter. John Ehrlichman, Nixon's domestic policy advisor, made a striking admission in a 2016 interview (published in Harper's Magazine after his death) that the War on Drugs was partly designed to politically disadvantage two of Nixon's perceived enemies: the anti-war left and Black Americans.

The international dimension was equally significant. The UN Convention on Psychotropic Substances (1971) established a framework for international drug control that led to psilocybin being scheduled in many countries around the world, creating global legal constraints on research that persisted for decades.

Part IV: Underground Continuity (1970s–1990s)

Ethnobotanical Documentation Continues

Even as institutional research halted, individual researchers continued to document psilocybin mushrooms in the field. The brothers Terence McKenna (1946–2000) and Dennis McKenna (b. 1950) conducted field research in the Amazon and published Psilocybin: Magic Mushroom Grower's Guide in 1976 under pseudonyms, making cultivation instructions available to a wide audience for the first time. Terence McKenna became a prominent writer and public speaker on psychedelics, developing theories about consciousness, time, and the role of psilocybin in human evolution — most famously the "Stoned Ape Hypothesis," which proposed that psilocybin mushroom use played a role in the expansion of human consciousness during our evolutionary prehistory. This hypothesis remains speculative and is not accepted by mainstream evolutionary biology, but it captured wide cultural attention.

Paul Stamets (b. 1955) — mycologist, author, and entrepreneur — began his career studying psilocybin-containing mushrooms in the Pacific Northwest during the 1970s and published his foundational species guide Psilocybin Mushrooms of the World in 1996. Stamets's contributions to mycology extend far beyond psychedelics, but his work on psilocybin species identification and his subsequent advocacy for psilocybin research (including the development of the "Stamets Stack" microdosing protocol) have made him a central figure in the contemporary psychedelic community.

Alexander Shulgin's Contributions

Alexander "Sasha" Shulgin (1925–2014) was an American chemist whose work on psychoactive substances during the 1980s and 1990s was enormously influential. Working from a laboratory behind his home in the San Francisco Bay Area — with a DEA Schedule I researcher's license — Shulgin synthesised and tested hundreds of novel psychoactive compounds on himself and a small group of colleagues, documenting the effects in meticulous detail. His two major books, PIHKAL: A Chemical Love Story (1991) and TIHKAL: The Tryptamines It Have Known And Loved (1997), published detailed synthesis routes and personal accounts for hundreds of compounds.

While Shulgin's direct work on psilocybin was limited, his contributions to the tryptamine pharmacology that psilocybin belongs to were foundational. TIHKAL includes detailed documentation of psilocybin's effects and chemistry, and Shulgin's approach — rigorous chemical characterisation combined with careful first-person phenomenological documentation — became a model for harm-reduction research methodology. He also played a key role in popularising MDMA (which he had re-synthesised in 1976), a substance that later became central to MAPS's clinical research programme.

Rick Strassman and the Return to Clinical Research

Rick Strassman (b. 1952), a psychiatrist at the University of New Mexico, conducted the first approved human psychedelic research since the early 1970s — administering DMT (dimethyltryptamine) intravenously to human volunteers between 1990 and 1995. Strassman's work, published in his 2000 book DMT: The Spirit Molecule, is important to psilocybin history not because it directly studied psilocybin but because it demonstrated that rigorous, approved human psychedelic research could be conducted again and opened the regulatory pathway that subsequent psilocybin researchers would follow. His experience navigating the DEA, institutional review boards, and the FDA established a template that Johns Hopkins, NYU, and other institutions later used.

Part V: The Modern Research Renaissance

Johns Hopkins 2006: The Landmark Study

The paper that most historians of the field mark as the beginning of the modern research renaissance was published in Psychopharmacology in 2006: Roland Griffiths, William Richards, Una McCann, and Robert Jesse, "Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance." The lead author, Roland Griffiths (1944–2023), was a Johns Hopkins professor with an impeccable career in drug dependence research — not the profile typically associated with psychedelic advocacy.

The study gave healthy volunteers either psilocybin (30 mg/70 kg) or Ritalin as an active placebo, in a controlled, supportive setting with two trained guides. It used rigorous double-blind methodology and validated outcome measures including the Mystical Experience Questionnaire (MEQ). Results were striking: a significant majority of psilocybin recipients reported the experience as one of the most meaningful of their lives, comparable in significance to the birth of a child or the death of a parent. At 14-month follow-up, participants continued to rate the experience highly and showed lasting positive changes in attitudes, mood, and behaviour as rated by community observers.

The 2006 Griffiths paper was significant not just for its findings but for its methodological rigour and its institutional context. Johns Hopkins was (and is) one of the world's most prestigious medical research institutions. A study from that institution, published in a mainstream pharmacology journal, with conservative, careful authors, using validated measures — this was a different kind of claim than anything that had come from the 1960s. It was, essentially, the document that made it scientifically respectable to study psilocybin again.

Imperial College London and the Neuroscience

While the Hopkins group developed the clinical trial framework, a parallel research programme at Imperial College London, initially led by David Nutt and Robin Carhart-Harris, developed the neuroimaging approach. Using fMRI and MEG brain scanning, the Imperial group produced foundational findings about how psilocybin affects the brain.

Their landmark 2012 paper in PNAS demonstrated that psilocybin decreases cerebral blood flow and BOLD signal in key regions of the default mode network (DMN) — the network associated with self-referential thinking and the maintenance of the narrative self. This finding provided a neurobiological framework for understanding ego dissolution and helped explain why high-dose psilocybin sessions might be therapeutically useful: by temporarily disrupting the rigid, ruminative patterns associated with the overactive DMN seen in depression, anxiety, and addiction, psilocybin may create a window of neuroplastic opportunity.

Subsequent Imperial studies produced the first evidence that psilocybin can reduce depressive symptoms in treatment-resistant patients (a pilot study published in 2016), and later contributed to the evidence base for COMPASS Pathways' Phase 2b trial of synthetic psilocybin (COMP360) for treatment-resistant depression — the largest psilocybin trial ever conducted at that point, with 233 participants across 22 sites in 10 countries.

MAPS and Psychedelic-Assisted Therapy

The Multidisciplinary Association for Psychedelic Studies (MAPS), founded by Rick Doblin in 1986, has been the primary non-profit research organisation driving psychedelic-assisted therapy into the clinical mainstream. While MAPS's primary focus has been MDMA-assisted therapy for PTSD (which received FDA Breakthrough Therapy designation in 2017 and was submitted for FDA approval in 2023), the organisation also funds psilocybin research and has been instrumental in creating the policy and regulatory frameworks within which all psychedelic medicine research now operates.

MAPS's model — deeply trained therapists, structured preparation and integration, careful participant selection, and a therapeutic container approach — has become the de facto standard for psychedelic-assisted therapy and has influenced how psilocybin research is conducted worldwide.

The Proliferation of Clinical Research (2010s–Present)

Following the 2006 Griffiths paper, the number of approved clinical studies of psilocybin increased rapidly. Key milestones:

• 2011: Charles Grob (UCLA) publishes psilocybin for end-of-life anxiety in cancer patients — significant positive findings.
• 2014: Matthew Johnson (Johns Hopkins) begins psilocybin for cigarette addiction research — results show 80% abstinence at 6 months in a small sample, extraordinary by comparison with any existing smoking cessation intervention.
• 2016: Griffiths group and Stephen Ross (NYU) both publish randomised controlled trials of psilocybin for anxiety and depression in cancer patients — both find large effect sizes.
• 2016: Imperial College London publishes first psilocybin for treatment-resistant depression open-label pilot study.
• 2019: Johns Hopkins Center for Psychedelic and Consciousness Research formally established — first centre of its kind in the US.
• 2020: Carhart-Harris et al. publish comparison of psilocybin therapy vs. escitalopram (SSRI) for depression in NEJM — psilocybin comparable to SSRI on primary outcome but with faster onset and better secondary outcomes.
• 2022: COMPASS Pathways Phase 2b trial results published in NEJM — 25 mg COMP360 shows significant antidepressant effect at 3 weeks, though 10 mg dose less clear.
• 2023: FDA grants Breakthrough Therapy designation to psilocybin for major depressive disorder (via COMPASS Pathways), signalling that the FDA considers psilocybin a potential breakthrough for a serious condition.

Part VI: Policy Reform — Oregon and Colorado

Oregon Measure 109 (2020)

In November 2020, Oregon voters passed Ballot Measure 109, the Oregon Psilocybin Services Act, by a margin of 55.8% to 44.2%. This was a landmark moment in the history of psilocybin policy: the first time any US jurisdiction had voted to create a regulated, legal framework for therapeutic psilocybin access.

Measure 109 does not legalise personal possession of psilocybin mushrooms generally — it creates a licensing framework for "psilocybin services," in which licensed "facilitators" administer psilocybin in licensed "service centres" to clients aged 21 and over. The framework explicitly does not require a medical or psychiatric diagnosis: it is a wellness model rather than a medical model. After a two-year development period during which the Oregon Health Authority developed regulations, licensing began in 2023. The first legal psilocybin service centres opened in Oregon in mid-2023, making Oregon the first US jurisdiction to offer legal, licensed psilocybin experiences outside of a clinical trial.

The Oregon model is being watched closely by researchers, policymakers, and advocates worldwide as the first real-world test of regulated therapeutic psilocybin access.

Colorado Proposition 122 (2022)

In November 2022, Colorado voters passed Proposition 122, the Natural Medicine Health Act, by a margin of 53.5% to 46.5%. Prop 122 created a broader framework than Oregon's: it decriminalised personal possession, cultivation, and sharing (but not sale) of several natural psychedelics including psilocybin mushrooms, psilocin, DMT, ibogaine, and mescaline (excluding peyote) — and created a licensed healing centre framework for supervised use, modelled partially on Oregon's approach.

Colorado's law represents the most expansive psychedelic policy reform in US history at the state level. Personal cultivation and sharing of psilocybin mushrooms for non-commercial purposes was effectively decriminalised for adults — a significant departure from the federal Schedule I status that continues to apply under federal law.

Global Developments

Beyond the US, psilocybin policy reform has progressed in several jurisdictions:

• Netherlands: Psilocybin mushrooms are illegal, but Psilocybe tampanensis sclerotia ("truffles") are legal and sold openly in "smart shops." Netherlands has been a de facto access point for Europeans seeking legal psilocybin experiences for decades, and Amsterdam has developed a substantial retreat and facilitation economy around this legal grey area.
• Jamaica: Psilocybin mushrooms have never been scheduled under Jamaican law. Legal retreat centres have operated there since the 2010s, serving international clients seeking psilocybin experiences in a legal context.
• Australia: In February 2023, the Therapeutic Goods Administration (TGA) approved psilocybin as a Scheduled 8 (controlled medicine) that authorized psychiatrists can prescribe for treatment-resistant depression — the first national-level prescription framework for psilocybin anywhere in the world.
• Canada: Health Canada has allowed individual Section 56 exemptions for terminally ill patients to use psilocybin, and has expanded access through the Special Access Programme.

Historical Topics — Subpages

Frequently Asked Questions

1. Who introduced psilocybin mushrooms to Western culture? R. Gordon Wasson, through his 1957 Life magazine article, is widely credited with introducing psilocybin mushrooms to Western audiences, though he built on the work of earlier ethnobotanists including Richard Evans Schultes and Blas Pablo Reko.
2. When was psilocybin first chemically isolated? Albert Hofmann isolated and synthesised psilocybin at Sandoz Laboratories in 1958, identifying it as the primary active compound in Psilocybe mexicana.
3. Why was psilocybin made illegal? Psilocybin was placed in Schedule I under the US Controlled Substances Act in 1970, largely as part of the Nixon administration's response to the counterculture of the 1960s. The scheduling decision was political as much as it was scientific, and was made without the evidence base that the FDA now requires for drug scheduling decisions.
4. When did scientific research on psilocybin resume? The modern research renaissance is generally dated to the 2006 Johns Hopkins study by Griffiths et al., though Rick Strassman's DMT research at UNM in the early 1990s preceded it and helped establish the regulatory pathway.
5. Is psilocybin legal anywhere? Psilocybin mushrooms are legal in Jamaica and unscheduled in some other jurisdictions. Psilocybin truffles are legally sold in the Netherlands. Oregon and Colorado have created regulated therapeutic access frameworks. Australia allows psychiatrists to prescribe psilocybin for treatment-resistant depression. Most of the world still classifies psilocybin as a controlled substance.
6. What is teonanácatl? The Aztec/Nahuatl term for sacred mushrooms, often translated as "flesh of the gods." It appears in sixteenth-century Spanish colonial records and is one of the clearest historical references to ceremonial psilocybin mushroom use in pre-Columbian Mesoamerica.
7. Who was Timothy Leary? A Harvard psychology lecturer who ran the Harvard Psilocybin Project from 1960–1963 and became a prominent — and controversial — public advocate for psychedelics during the 1960s counterculture. His dismissal from Harvard and subsequent advocacy contributed to both the cultural spread of psychedelics and the political backlash that led to criminalisation.
8. What is the Johns Hopkins Center for Psychedelic Research? Formally established in 2019, it is the first US research centre dedicated to psychedelic science, building on the group's work since the early 2000s. It has produced landmark studies on psilocybin for depression, addiction, and end-of-life anxiety.
9. What is Oregon Measure 109? A 2020 ballot initiative that created the first regulated therapeutic psilocybin access framework in the United States. Licensed facilitators can administer psilocybin to adults aged 21+ in licensed service centres. The first service centres opened in 2023.
10. Are there Indigenous communities still practising traditional mushroom ceremonies? Yes. Mazatec communities in Oaxaca, Mexico continue the velada tradition, as do other indigenous groups. Contemporary harm-reduction and psychedelic advocacy communities increasingly emphasise the importance of respecting indigenous sovereignty over these traditions and opposing cultural appropriation.